Korea Arlico Pharm Co., Ltd. (260660) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Korea Arlico Pharm Co., Ltd. (260660:KRX), powered by AI.

Current Price
₩3,700
P/E Ratio
-10.4
Market Cap
56.7B
Sector
Healthcare
What is the Korea Arlico Pharm Co., Ltd. stock price forecast?

Korea Arlico Pharm Co., Ltd. is currently trading at ₩3,700. View real-time AI analysis on Alpha Lenz.

What is Korea Arlico Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Korea Arlico Pharm Co., Ltd. on Alpha Lenz.

What is Korea Arlico Pharm Co., Ltd.'s P/E ratio?

Korea Arlico Pharm Co., Ltd.'s P/E ratio is -10.4.

Korea Arlico Pharm Co., Ltd.

KRX · 260660
₩3,700
Ask about Korea Arlico Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Korea Arlico Pharm Co., Ltd. trades at a P/E of -10.4 (undervalued) with modest ROE of -6.4%. 3Y revenue CAGR of 10.8% highlights clear growth momentum.

Ask for details

Company Overview

Korea Arlico Pharm Co., Ltd. is a prominent pharmaceutical company engaged in the development, manufacture, and distribution of medicinal products. Specializing in the production of both prescription drugs and over-the-counter medicines, the company plays a vital role in the healthcare industry. Its robust portfolio includes therapeutics aimed at treating a variety of ailments, contributing significantly to public health. Korea Arlico Pharm is noted for its emphasis on innovation and rigorous quality control measures, ensuring the safety and efficacy of its products. Operating in the competitive landscape of pharmaceuticals, the company serves a diverse clientele including hospitals, pharmacies, and healthcare providers. As a participant in the broader healthcare and pharmaceuticals sector, Korea Arlico Pharm Co., Ltd. is pivotal in addressing the demands of an aging population and the growing need for effective medical interventions globally. The company's continuous investment in research and development underscores its commitment to advancing medical science and delivering high-quality healthcare solutions.

CEO이항구
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2024

Profile

₩56,709,977,700Market Cap
₩190,435,818,360Revenue
15.33MShares Out
0Employees

Margins

52.40%Gross
1.37%EBITDA
-2.71%Operating
-3.24%Pre-Tax
-2.81%Net

Valuation

-10.37P/E
0.70P/B
0.29EV/Sales
34.81EV/EBITDA
-4.53P/FCF

Growth (CAGR)

10.76%Rev 3Yr
10.46%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.10%ROA
-6.35%ROE
-2.35%ROIC

Financial Health

₩15,483,963,130Cash & Cash Equivalents
₩77,199,737,130Net Debt
116.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Korea Arlico Pharm Co., Ltd. (ticker: 260660) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $56.7B.

The current price is ₩3,700 with a P/E ratio of -10.37x and P/B of 0.7x.

ROE is -6.35% and operating margin is -2.71%. Annual revenue is $190.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Korea Arlico Pharm Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩3,700 | Alpha Lenz